Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 762Lung Neoplasms 339Ovarian Neoplasms 318Breast Neoplasms 277Fallopian Tube Neoplasms 158Triple Negative Breast Neoplasms 143Small Cell Lung Carcinoma 140Neoplasms 134Squamous Cell Carcinoma of Head and Neck 122Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 84Head and Neck Neoplasms 80Endometrial Neoplasms 76Uterine Cervical Neoplasms 70Esophageal Neoplasms 70Adenocarcinoma of Lung 68Neuroblastoma 55Central Nervous System Neoplasms 52Lymphoma, Large B-Cell, Diffuse 49Carcinoma 49Brain Neoplasms 48Recurrence 47Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Lymphoma, Non-Hodgkin 31

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Immune Checkpoint Inhibitors 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Solid Cancers × Carboplatin × Clear all
NCT01301716 2016-11-02

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Genentech, Inc.

Phase 1 Completed
75 enrolled

Solid Cancers

NCT00927589 2015-12-10

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Genentech, Inc.

Phase 1 Completed
59 enrolled 19 charts

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡